InsiderSignal.AI

InsiderSignal.ai

UTHR - United Therapeutics Corp

Insider Sale by Edgemond James (CFO, TREASURER)

1 Month
After Trade
Before Trade

Loading data...

Trade Summary

1 week ago, Edgemond James, serving as CFO, TREASURER at United Therapeutics Corp (UTHR), sold 10,000 shares at $561.50 per share, for a total transaction value of $5,614,984.00. Following this transaction, Edgemond James now holds 18,876 shares of UTHR.

This sale represents a 35.00% decrease in Edgemond James's stake in the company. This is considered a high-conviction trade given the significant change in ownership.

The trade was executed on Thursday, April 2, 2026 and publicly disclosed via SEC Form 4 filing on Monday, April 6, 2026, 4 days after the trade was made.

United Therapeutics Corp operates in the HEALTHCARE sector, specifically within the DRUG MANUFACTURERS - SPECIALTY & GENERIC industry. Insider selling activity in this sector can provide valuable signals about industry trends and company-specific developments.

Edgemond James

Edgemond James

CFO, TREASURER

James Edgemond is the Chief Financial Officer and Treasurer of United Therapeutics Corporation, a position he has held since his promotion in March 2015[[1]](https://unither.com/about-us/leadership/james-edgemond). He began his tenure at United Therapeutics in January 2013 as Treasurer and Vice President, Strategic Financial Planning[[1]](https://unither.com/about-us/leadership/james-edgemond). Edgemond brings extensive financial management experience from his previous role as Vice President, Corporate Controller, and Treasurer at Clark Construction Group from 2008 to 2013[[1]](https://unither.com/about-us/leadership/james-edgemond). His career also includes significant tenure at The Corporate Executive Board Company, where he served in various finance roles from 1998 to 2008, including Executive Director of Finance from 2005 to 2008[[1]](https://unither.com/about-us/leadership/james-edgemond). He started his professional career as a public accountant at KPMG Peat Marwick LLP from 1990 to 1998, advancing to Senior Manager before departing[[1]](https://unither.com/about-us/leadership/james-edgemond). In his current role overseeing United Therapeutics' financial operations, Edgemond actively manages company stock and exercises stock options as part of his executive compensation[[2]](https://www.investing.com/news/insider-trading-news/united-therapeutics-cfo-edgemond-sells-94m-in-uthr-stock-93CH-4353340). Recent insider trading activity shows he sold $9.4 million in company stock in November 2025 and exercised stock options for 21,000 shares, reflecting his ongoing involvement in the company's ownership structure[[2]](https://www.investing.com/news/insider-trading-news/united-therapeutics-cfo-edgemond-sells-94m-in-uthr-stock-93CH-4353340). His financial leadership spans multiple industry sectors, from construction and strategic advisory services to biopharmaceutical operations.

View full insider profile →

Trade Price

$561.50

Quantity

10,000

Total Value

$5,614,984.00

Shares Owned

18,876

Trade Date

Thursday, April 2, 2026

7 days ago

SEC Filing Date

Monday, April 6, 2026

Filed 4 days after trade

HEALTHCAREDRUG MANUFACTURERS - SPECIALTY & GENERIC

About United Therapeutics Corp

Company Overview

No company information available
View news mentioning UTHR

💬 Want Deeper Insight?

Use our AI assistant to ask questions about this trade, the insider, or the company.

Chat with AI

Share this trade

https://insidersignal.ai/trade/5420752

🚀 Track Insider Trades in Real-Time

Create a free account to access our full database of insider trades, AI-powered analysis, price alerts, and discover what corporate executives are buying and selling.

Create Free AccountLearn More

✓ Free forever plan available  •  ✓ No credit card required  •  ✓ Cancel anytime